Recommendations to advance equity in tobacco control.

Autor: Mills SD; Department of Health Behavior, University of North Carolina, Chapel Hill, North Carolina, USA sarahmills@unc.edu.; Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Rosario C; Department of Public Health Education, The University of North Carolina at Greensboro, Greensboro, North Carolina, USA., Yerger VB; Department of Social and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA., Kalb MD; Department of Health Behavior, University of North Carolina, Chapel Hill, North Carolina, USA., Ribisl KM; Department of Health Behavior, University of North Carolina, Chapel Hill, North Carolina, USA.; Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Publikováno v: Tobacco control [Tob Control] 2024 Nov 10; Vol. 33 (e2), pp. e246-e253. Date of Electronic Publication: 2024 Nov 10.

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

Autor: Arnon D. Cohen, MD, MPH, PhD, Ronald Vender, MD, FRCPC, Luigi Naldi, MD, Robert E. Kalb, MD, Tiago Torres, MD, PhD, Murlidhar Rajagopalan, MD, Joelle van der Walt, PhD, Lluís Puig, MD (Hon), PhD, Helen S. Young, MB ChB, PhD, FRCP

Publikováno v: JAAD International, Vol 1, Iss 2, Pp 224-230 (2020)

Background: As biosimilars have become available in various parts of the world, the International Psoriasis Council has reviewed aspects of their use. Objective: To provide consensus statements from the Biosimilar Working Group about the use of biosi

Externí odkaz: https://doaj.org/article/0b6f4a54dbc947d2a36e56b94f2b29b1

Multiple Sclerosis : A Guide for Families, Third Edition

Autor: Rosalind C. Kalb, MD

Because most people who are diagnosed with MS are between the ages of 15-55 years, the disease has a significant impact, not only on the individual with the disease, but also on the family members and loved ones whose lives are interwoven with them.

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.

Autor: Burshtein, Joshua¹ (AUTHOR) jburshtein13@gmail.com, Shah, Milaan¹ (AUTHOR), Zakria, Danny¹ (AUTHOR), Lockshin, Benjamin^2,3 (AUTHOR), Crowley, Jeff⁴ (AUTHOR), Merola, Joseph F.⁵ (AUTHOR), Gordon, Ken⁶ (AUTHOR), Shahriari, Mona⁷ (AUTHOR), Korman, Neil J.⁸ (AUTHOR), Chovatiya, Raj⁹ (AUTHOR), Kalb, Robert¹⁰ (AUTHOR), Lebwohl, Mark¹ (AUTHOR)

Publikováno v: Dermatology & Therapy. Feb2024, Vol. 14 Issue 2, p323-339. 17p.

Biosimilars in Dermatology Review.

Autor: Baker, John, Kalb, Robert

Publikováno v: Journal of Psoriasis & Psoriatic Arthritis; Jan2024, Vol. 9 Issue 1, p28-35, 8p